RedHill Biopharma (RDHL) News Today $2.26 +0.19 (+9.18%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$2.24 -0.02 (-0.88%) As of 04/17/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period RedHill Biopharma receives non-compliance letter from NasdaqApril 18 at 4:16 PM | markets.businessinsider.comRedHill Biopharma Ltd.: RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity DeficiencyApril 18 at 6:37 AM | finanznachrichten.deRedHill Biopharma announces publication in journal on OpaganibApril 17 at 8:36 PM | markets.businessinsider.comRedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity DeficiencyApril 17 at 4:01 PM | prnewswire.comRedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market DisruptionApril 16 at 7:00 AM | prnewswire.comRedHill Biopharma (NASDAQ:RDHL) Coverage Initiated at StockNews.comApril 14, 2025 | americanbankingnews.comRedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational HighlightsApril 10, 2025 | finanznachrichten.deRedHill Biopharma Announces Full-Year 2024 Financial Results and Operational HighlightsApril 10, 2025 | prnewswire.comRedHill Biopharma to submit UK MAA for TaliciaMarch 18, 2025 | markets.businessinsider.comRedHill Biopharma Ltd.: RedHill Biopharma to Submit FDA-Approved Talicia for UK Marketing AuthorisationMarch 18, 2025 | finanznachrichten.deRedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing AuthorisationMarch 18, 2025 | prnewswire.comRedHill Biopharma announces plans to advance program for Crohn’s diseaseMarch 13, 2025 | markets.businessinsider.comRedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 ResultsMarch 12, 2025 | prnewswire.comRedHill Presents Business Update at the Sachs' European Life Sciences CEO ForumFebruary 27, 2025 | prnewswire.comRedHill and Hyloris sign agreement for Bekinda’s developmentFebruary 26, 2025 | msn.comRedHill Biopharma licenses RHB-102 for global commercialization to HylorisFebruary 25, 2025 | markets.businessinsider.comRedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus RoyaltiesFebruary 25, 2025 | prnewswire.comEarnings call transcript: RedHill Biopharma Q1 2022 sees revenue dipFebruary 7, 2025 | msn.comRedHill Biopharma Launches Phase 2 Trial For Advanced Prostate Cancer TreatmentFebruary 6, 2025 | markets.businessinsider.comRedHill tests opaganib with Bayer's drug in prostate cancer studyFebruary 4, 2025 | msn.comRedHill Biopharma Ltd.: RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate CancerFebruary 4, 2025 | finanznachrichten.deRedHill Biopharma begins Phase 2 study of prostate cancer combinationFebruary 4, 2025 | markets.businessinsider.comRedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate CancerFebruary 4, 2025 | prnewswire.comRedHill stock rises on expanded Medicare coverageJanuary 21, 2025 | msn.comRedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing PublishedJanuary 21, 2025 | prnewswire.comRadioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced DevelopmentDecember 10, 2024 | prnewswire.comRedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme CourtDecember 2, 2024 | prnewswire.comRedHill Biopharma to Present Opaganib at U.S. Defense ConferenceOctober 29, 2024 | markets.businessinsider.comRedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRNDOctober 28, 2024 | prnewswire.comRedHill Biopharma and Duke Collaborate on Opaganib DevelopmentOctober 22, 2024 | markets.businessinsider.comRedHill Biopharma signs research pact with Duke University School of MedicineOctober 22, 2024 | markets.businessinsider.comRedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation InjuryOctober 22, 2024 | prnewswire.comRedHill: BARDA Selects Opaganib For Development & Funding As Medical Countermeasure To Treat EbolaOctober 14, 2024 | markets.businessinsider.comRedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola TreatmentOctober 14, 2024 | prnewswire.comRedHill Biopharma Secures Opaganib COVID-19 PatentOctober 1, 2024 | finance.yahoo.comRedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million CaliforniansOctober 1, 2024 | prnewswire.comRedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041September 30, 2024 | prnewswire.comRedHill Biopharma Ltd. (NASDAQ:RDHL) Sees Large Decline in Short InterestRedHill Biopharma Ltd. (NASDAQ:RDHL - Get Free Report) saw a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 49,800 shares, a drop of 58.7% from the August 31st total of 120,500 shares. Currently, 3.9% of the shares of the company are sold short. Based on an average daily volume of 317,400 shares, the days-to-cover ratio is presently 0.2 days.September 26, 2024 | marketbeat.comRedHill Biopharma (NASDAQ:RDHL) Stock Price Passes Below 200-Day Moving Average of $10.89RedHill Biopharma (NASDAQ:RDHL) Stock Price Crosses Below 200 Day Moving Average of $10.89September 12, 2024 | marketbeat.comRedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology GuidelinesSeptember 9, 2024 | prnewswire.comRedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 5, 2024 | prnewswire.comRedHill Biopharma (NASDAQ:RDHL) Stock Passes Below 200 Day Moving Average of $11.02RedHill Biopharma (NASDAQ:RDHL) Shares Cross Below 200-Day Moving Average of $11.02September 4, 2024 | marketbeat.comREDHILL B.AD 10000/IL-,01 (2RH.MU)September 3, 2024 | au.finance.yahoo.comNew Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 MortalitySeptember 3, 2024 | prnewswire.comRedHill Biopharma Ltd.: RedHill Biopharma Announces First Half 2024 Business HighlightsAugust 30, 2024 | finanznachrichten.deRedHill Biopharma Announces First Half 2024 Business HighlightsAugust 29, 2024 | prnewswire.comShort Interest in RedHill Biopharma Ltd. (NASDAQ:RDHL) Declines By 94.8%RedHill Biopharma Ltd. (NASDAQ:RDHL - Get Free Report) was the recipient of a large decline in short interest during the month of August. As of August 15th, there was short interest totalling 21,700 shares, a decline of 94.8% from the July 31st total of 417,400 shares. Based on an average daily trading volume, of 304,200 shares, the short-interest ratio is presently 0.1 days. Approximately 1.7% of the company's stock are short sold.August 27, 2024 | marketbeat.comRedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, NeuroblastomaAugust 26, 2024 | prnewswire.comRedHill Biopharma (NASDAQ:RDHL) Research Coverage Started at StockNews.comStockNews.com started coverage on RedHill Biopharma in a research note on Saturday. They issued a "hold" rating for the company.August 24, 2024 | marketbeat.comRedhill Biopharma Ltd (2RH0.SG)August 22, 2024 | nz.finance.yahoo.com Get RedHill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Email Address RDHL Media Mentions By Week RDHL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RDHL News Sentiment▼0.140.52▲Average Medical News Sentiment RDHL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RDHL Articles This Week▼71▲RDHL Articles Average Week Get RedHill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Incannex Healthcare News Today Moleculin Biotech News Today Bright Green News Today Rallybio News Today Minerva Neurosciences News Today Hoth Therapeutics News Today Traws Pharma News Today PHAXIAM Therapeutics News Today BioXcel Therapeutics News Today Phio Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RDHL) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RedHill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share RedHill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RDHL Stock Free RDHL Stock Alerts